Skip To Main Content
Savrina Manhas on Muck Rack

Savrina Manhas

As seen in: BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Savrina

Contact Savrina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HIV-1 envelopes from virions that persist in plasma on antiretroviral therapy show reduced susceptibility to autologous immunoglobulins and variable sensitivity to broadly neutralizing monoclonal antibodies

|
By Savrina Manhas, Joseph Brooker, Cory Shetler, Kerri J. Penrose
| BioRxiv
Abstract Despite adherence to antiretroviral therapy (ART), low levels of plasma virus persist in most individuals with HIV-1. In a small subset of these individuals, this non-suppressible viremia is detected by routine clinical testing (plasma HIV-1 RNA >20 copies/ml) and has been shown to be of clonal cellular origin.
Open in Who Shared Issue with article?

Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys

|
By Jared D. Pitts, Thomas Aeschbacher, Savrina Manhas, Josolyn Chan
| BioRxiv
Abstract Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in high-risk populations. Although prophylactic options are available, there are no effective oral therapeutics for RSV infection. Obeldesivir (ODV) is an orally bioavailable prodrug of the nucleoside analog GS-441524, which is converted intracellularly to its active nucleoside triphosphate and inhibits the RSV RNA polymerase.
Open in Who Shared Issue with article?
See all 2 articles